利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

804 条记录 (耗时 0.044 秒)

    ISOLATION AND PURIFICATION OF ANTI-IL-13 ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY
    71.
    发明公开
    ISOLATION AND PURIFICATION OF ANTI-IL-13 ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY 审中-公开
    澳大利亚抗血清抗IL-13抗原蛋白分离蛋白A-AFFINITÄTSCHROMATOGRAFIE

    公开(公告)号：EP3037104A1

    公开(公告)日：2016-06-29

    申请号：EP15189425.0

    申请日：2010-10-20

    申请人： AbbVie Inc.

    发明人： HICKMAN, Robert

    IPC分类号： A61K39/395 ,  C07K16/06 ,  C07K16/24

    摘要： Disclosed herein are methods for the isolation and purification of anti- IL- 13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.

    摘要翻译： 本文公开了分离和纯化抗IL-13抗体的方法，其中使用亲和层析步骤导致抗体组合物对于药物用途而言足够纯。 本文描述的方法包括pH病毒还原/失活，超滤/渗滤，亲和层析（例如蛋白A亲和层析），离子交换层析和疏水层析。 此外，本发明涉及包含本发明的一种或多种抗体的药物组合物。

    NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    77.
    发明公开
    NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A 有权
    新型的磷酸二酯酶抑制剂化合物10A

    公开(公告)号：EP2970258A1

    公开(公告)日：2016-01-20

    申请号：EP14709693.7

    申请日：2014-03-13

    申请人： AbbVie Deutschland GmbH & Co KG ,  AbbVie Inc.

    发明人： GENESTE, Hervé ,  OCHSE, Michael ,  DRESCHER, Karla ,  BEHL, Berthold ,  LAPLANCHE, Loic ,  DINGES, Jürgen ,  JAKOB, Clarissa

    IPC分类号： C07D471/04 ,  C07D519/00 ,  A61P25/00 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/444 ,  A61K31/506

    CPC分类号： C07D471/04 ,  C07D519/00

    摘要： The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

    摘要翻译： 本发明涉及式（I）的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐。 在式I中，变量Het，A，X，Y，Z，R 1，R 2，R 3，R 4，R 5和Q如权利要求中所定义。 式I化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐是10A型磷酸二酯酶的抑制剂。 因此，本发明还涉及式I化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐在制备药物中的用途，因此其适用于治疗或控制医学病症 选自神经障碍和精神障碍，用于改善与这种障碍相关的症状并降低这种障碍的风险。

    SYRINGE WITH TWO-STAGE SEALING PRESSURE
    78.
    发明公开
    SYRINGE WITH TWO-STAGE SEALING PRESSURE 审中-公开
    。ZE。。。。。。。。。

    公开(公告)号：EP2956191A1

    公开(公告)日：2015-12-23

    申请号：EP13714114.9

    申请日：2013-03-14

    申请人： AbbVie Inc.

    发明人： MACKEY, Sean, E. ,  ZHOU, Ji ,  GIBLER, Martin, J. ,  LEE, Dennis ,  WIESNER, Bryan, L.

    IPC分类号： A61M5/178 ,  A61M5/31 ,  A61M5/315 ,  A61J1/14

    CPC分类号： A61M5/31513 ,  A61J7/0053 ,  A61J15/0015 ,  A61J15/0061 ,  A61J15/0069 ,  A61J15/0076 ,  A61M5/002 ,  A61M5/14546 ,  A61M5/3135 ,  A61M5/31501 ,  A61M5/31505 ,  A61M2005/3101 ,  A61M2005/3106 ,  A61M2005/3131 ,  A61M2005/31506 ,  A61M2205/8206

    摘要： A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel. The barrel includes a first portion with a first inner diameter and a second portion with a second inner diameter that is larger than the first inner diameter. The sealing member engages the first portion of the barrel to give rise to a first contact pressure when the barrel is filled with product. The first contact pressure is sufficient to maintain a gas-tight seal over the expected temperature ranges -25 DEG C to 40 DEG C. A first force is applied to the plunger to overcome the first contact pressure and move the plunger out of the first portion and into the second portion to dispense product. The sealing member engages the second portion of the barrel to give rise to a second contact pressure that is lower than the first contact pressure. A second force lower than the first force is sufficient to overcome the second contact pressure and move the plunger in the second portion to continue dispensing product. The syringe may include a restraining element for accommodating expansion of the product during freezing.

    摘要翻译： 注射器包括筒体，柱塞和在柱塞和筒体之间产生密封的密封构件。 枪管包括具有第一内径的第一部分和具有大于第一内径的第二内径的第二部分。 密封构件与筒体的第一部分接合以在桶体填充产品时产生第一接触压力。 第一接触压力足以在-25℃至40℃的预期温度范围内保持气密密封。将第一力施加到柱塞以克服第一接触压力并将柱塞移出第一部分 并进入第二部分分配产品。 密封构件接合桶的第二部分以产生低于第一接触压力的第二接触压力。 低于第一力的第二力足以克服第二接触压力并将柱塞移动到第二部分中以继续分配产品。 注射器可以包括用于在冷冻期间容纳产品的膨胀的约束元件。